FSWA
NBIX icon

Financial Synergies Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Financial Synergies Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9
Closed -$1.24K – 307
2024
Q1 		$1.24K Sell
9
-3
-25% -$410 ﹤0.01% 375
2023
Q4 		$1.43K Buy
+12
New +$1.38K ﹤0.01% 283
2023
Q1 		– Sell
-12
Closed -$1.43K – 507
2022
Q4 		$1.43K Hold
12
– – ﹤0.01% 283
2022
Q3 		$1.27K Buy
+12
New +$1.22K ﹤0.01% 269

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Financial Synergies Wealth Advisors's NBIX Position: Q2 2024 in Review

Financial Synergies Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 9 shares — an estimated $1.24K sold.

Financial Synergies Wealth Advisors first reported a position in NBIX in Q3 2022 and held it in 4 quarters. The position peaked at $1.43K in Q4 2023. 595 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Financial Synergies Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Financial Synergies Wealth Advisors sold 9 Neurocrine Biosciences shares in Q2 2024, an estimated $1.24K.
  • Financial Synergies Wealth Advisors first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 4 quarters.
  • Financial Synergies Wealth Advisors's Neurocrine Biosciences position peaked at $1.43K in Q4 2023.
  • 595 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Financial Synergies Wealth Advisors's 13F filing for Q2 2024, filed 23 Jul 2024.